Granules' arm completes audit with USFDA
New Delhi: Pharma firm Granules India said its US subsidiary has received an observation from the USFDA on completion of the inspection.
"Granules Pharmaceuticals Inc, a wholly-owned foreign subsidiary of the company located in Chantilly, Virginia, US completed its first audit from December 4-8, 2017 by the USFDA (US Food and Drug Administration) with one observation," the company said in a BSE filing.
The company, however, did not elaborate on the nature of the observation.
"Granules Pharmaceuticals Inc will respond to this observation within the stipulated time period," it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd